A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease
- Autores
- Bustamante, Juan Manuel; Sánchez Valdéz, Fernando Javier; Padilla, Ángel Marcelo; White, Brooke; Wang, Wei; Tarleton, Rick L.
- Año de publicación
- 2020
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- A major contributor to treatment failure in Chagas disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is that current treatment regimens do not address the drug insensitivity of transiently dormant T. cruzi amastigotes. Here, we demonstrated that use of a currently available drug in a modified treatment regimen of higher individual doses, given less frequently over an extended treatment period, could consistently extinguish T. cruzi infection in three mouse models of Chagas disease. Once per week administration of benznidazole at a dose 2.5 to 5 times the standard daily dose rapidly eliminated actively replicating parasites and ultimately eradicated the residual, transiently dormant parasite population in mice. This outcome was initially confirmed in “difficult to cure” mouse infection models using immunological, parasitological, and molecular biological approaches and ultimately corroborated by whole organ analysis of optically clarified tissues using light sheet fluorescence microscopy (LSFM). This tool was effective for monitoring pathogen load in intact organs, including detection of individual dormant parasites, and for assessing treatment outcomes. LSFM-based analysis also suggested that dormant amastigotes of T. cruzi may not be fully resistant to trypanocidal compounds such as benznidazole. Collectively, these studies provide important information on the phenomenon of dormancy in T. cruzi infection in mice, demonstrate methods to therapeutically override dormancy using a currently available drug, and provide methods to monitor alternative therapeutic approaches for this, and possibly other, low-density infectious agents.
Fil: Bustamante, Juan Manuel. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Sánchez Valdéz, Fernando Javier. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; Argentina
Fil: Padilla, Ángel Marcelo. University of Georgia; Estados Unidos
Fil: White, Brooke. University of Georgia; Estados Unidos
Fil: Wang, Wei. University of Georgia; Estados Unidos
Fil: Tarleton, Rick L.. University of Georgia; Estados Unidos - Materia
-
DORMANCY
CHAGAS
TREATMENT
CLARIFICATION - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/141920
Ver los metadatos del registro completo
id |
CONICETDig_f5539bf8b1b4a07357ad999ff77693e7 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/141920 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas diseaseBustamante, Juan ManuelSánchez Valdéz, Fernando JavierPadilla, Ángel MarceloWhite, BrookeWang, WeiTarleton, Rick L.DORMANCYCHAGASTREATMENTCLARIFICATIONhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3A major contributor to treatment failure in Chagas disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is that current treatment regimens do not address the drug insensitivity of transiently dormant T. cruzi amastigotes. Here, we demonstrated that use of a currently available drug in a modified treatment regimen of higher individual doses, given less frequently over an extended treatment period, could consistently extinguish T. cruzi infection in three mouse models of Chagas disease. Once per week administration of benznidazole at a dose 2.5 to 5 times the standard daily dose rapidly eliminated actively replicating parasites and ultimately eradicated the residual, transiently dormant parasite population in mice. This outcome was initially confirmed in “difficult to cure” mouse infection models using immunological, parasitological, and molecular biological approaches and ultimately corroborated by whole organ analysis of optically clarified tissues using light sheet fluorescence microscopy (LSFM). This tool was effective for monitoring pathogen load in intact organs, including detection of individual dormant parasites, and for assessing treatment outcomes. LSFM-based analysis also suggested that dormant amastigotes of T. cruzi may not be fully resistant to trypanocidal compounds such as benznidazole. Collectively, these studies provide important information on the phenomenon of dormancy in T. cruzi infection in mice, demonstrate methods to therapeutically override dormancy using a currently available drug, and provide methods to monitor alternative therapeutic approaches for this, and possibly other, low-density infectious agents.Fil: Bustamante, Juan Manuel. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Sánchez Valdéz, Fernando Javier. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; ArgentinaFil: Padilla, Ángel Marcelo. University of Georgia; Estados UnidosFil: White, Brooke. University of Georgia; Estados UnidosFil: Wang, Wei. University of Georgia; Estados UnidosFil: Tarleton, Rick L.. University of Georgia; Estados UnidosAmerican Association for the Advancement of Science2020-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/141920Bustamante, Juan Manuel; Sánchez Valdéz, Fernando Javier; Padilla, Ángel Marcelo; White, Brooke; Wang, Wei; et al.; A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease; American Association for the Advancement of Science; Science Translational Medicine; 12; 567; 10-2020; 1-121946-6242CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1126/scitranslmed.abb7656info:eu-repo/semantics/altIdentifier/url/https://www.science.org/doi/10.1126/scitranslmed.abb7656info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:45:15Zoai:ri.conicet.gov.ar:11336/141920instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:45:15.328CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease |
title |
A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease |
spellingShingle |
A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease Bustamante, Juan Manuel DORMANCY CHAGAS TREATMENT CLARIFICATION |
title_short |
A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease |
title_full |
A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease |
title_fullStr |
A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease |
title_full_unstemmed |
A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease |
title_sort |
A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease |
dc.creator.none.fl_str_mv |
Bustamante, Juan Manuel Sánchez Valdéz, Fernando Javier Padilla, Ángel Marcelo White, Brooke Wang, Wei Tarleton, Rick L. |
author |
Bustamante, Juan Manuel |
author_facet |
Bustamante, Juan Manuel Sánchez Valdéz, Fernando Javier Padilla, Ángel Marcelo White, Brooke Wang, Wei Tarleton, Rick L. |
author_role |
author |
author2 |
Sánchez Valdéz, Fernando Javier Padilla, Ángel Marcelo White, Brooke Wang, Wei Tarleton, Rick L. |
author2_role |
author author author author author |
dc.subject.none.fl_str_mv |
DORMANCY CHAGAS TREATMENT CLARIFICATION |
topic |
DORMANCY CHAGAS TREATMENT CLARIFICATION |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
A major contributor to treatment failure in Chagas disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is that current treatment regimens do not address the drug insensitivity of transiently dormant T. cruzi amastigotes. Here, we demonstrated that use of a currently available drug in a modified treatment regimen of higher individual doses, given less frequently over an extended treatment period, could consistently extinguish T. cruzi infection in three mouse models of Chagas disease. Once per week administration of benznidazole at a dose 2.5 to 5 times the standard daily dose rapidly eliminated actively replicating parasites and ultimately eradicated the residual, transiently dormant parasite population in mice. This outcome was initially confirmed in “difficult to cure” mouse infection models using immunological, parasitological, and molecular biological approaches and ultimately corroborated by whole organ analysis of optically clarified tissues using light sheet fluorescence microscopy (LSFM). This tool was effective for monitoring pathogen load in intact organs, including detection of individual dormant parasites, and for assessing treatment outcomes. LSFM-based analysis also suggested that dormant amastigotes of T. cruzi may not be fully resistant to trypanocidal compounds such as benznidazole. Collectively, these studies provide important information on the phenomenon of dormancy in T. cruzi infection in mice, demonstrate methods to therapeutically override dormancy using a currently available drug, and provide methods to monitor alternative therapeutic approaches for this, and possibly other, low-density infectious agents. Fil: Bustamante, Juan Manuel. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Sánchez Valdéz, Fernando Javier. University of Georgia; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Salta. Instituto de Patología Experimental. Universidad Nacional de Salta. Facultad de Ciencias de la Salud. Instituto de Patología Experimental; Argentina Fil: Padilla, Ángel Marcelo. University of Georgia; Estados Unidos Fil: White, Brooke. University of Georgia; Estados Unidos Fil: Wang, Wei. University of Georgia; Estados Unidos Fil: Tarleton, Rick L.. University of Georgia; Estados Unidos |
description |
A major contributor to treatment failure in Chagas disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is that current treatment regimens do not address the drug insensitivity of transiently dormant T. cruzi amastigotes. Here, we demonstrated that use of a currently available drug in a modified treatment regimen of higher individual doses, given less frequently over an extended treatment period, could consistently extinguish T. cruzi infection in three mouse models of Chagas disease. Once per week administration of benznidazole at a dose 2.5 to 5 times the standard daily dose rapidly eliminated actively replicating parasites and ultimately eradicated the residual, transiently dormant parasite population in mice. This outcome was initially confirmed in “difficult to cure” mouse infection models using immunological, parasitological, and molecular biological approaches and ultimately corroborated by whole organ analysis of optically clarified tissues using light sheet fluorescence microscopy (LSFM). This tool was effective for monitoring pathogen load in intact organs, including detection of individual dormant parasites, and for assessing treatment outcomes. LSFM-based analysis also suggested that dormant amastigotes of T. cruzi may not be fully resistant to trypanocidal compounds such as benznidazole. Collectively, these studies provide important information on the phenomenon of dormancy in T. cruzi infection in mice, demonstrate methods to therapeutically override dormancy using a currently available drug, and provide methods to monitor alternative therapeutic approaches for this, and possibly other, low-density infectious agents. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-10 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/141920 Bustamante, Juan Manuel; Sánchez Valdéz, Fernando Javier; Padilla, Ángel Marcelo; White, Brooke; Wang, Wei; et al.; A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease; American Association for the Advancement of Science; Science Translational Medicine; 12; 567; 10-2020; 1-12 1946-6242 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/141920 |
identifier_str_mv |
Bustamante, Juan Manuel; Sánchez Valdéz, Fernando Javier; Padilla, Ángel Marcelo; White, Brooke; Wang, Wei; et al.; A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease; American Association for the Advancement of Science; Science Translational Medicine; 12; 567; 10-2020; 1-12 1946-6242 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1126/scitranslmed.abb7656 info:eu-repo/semantics/altIdentifier/url/https://www.science.org/doi/10.1126/scitranslmed.abb7656 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
American Association for the Advancement of Science |
publisher.none.fl_str_mv |
American Association for the Advancement of Science |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614491949498368 |
score |
13.070432 |